Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of TAKC-02 Inhalation Solution in Healthy Adult Males
NCT05018533Phase 1Completed
- Sponsor
- TAK-Circulator Corporation
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAKC-02 in asthma (14 cohorts), sponsored by TAK-Circulator Corporation. Primary endpoint: Changes in the rate of adverse events. Started Aug 2021; status: completed.
02
Drugs
TAKC-02
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05018533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018533.